“Technological Advancement in Genomic Sequencing”
The rapid pace of technological advancements in genomic sequencing has significantly contributed to the transformation of oncology diagnostics and treatment in New Zealand. In particular, the evolution of Next-Generation Sequencing (NGS) technology has provided more accurate, efficient, and scalable solutions for cancer detection and treatment planning. The ability of NGS to analyze large volumes of genetic data quickly and with high precision enables clinicians to uncover critical genetic mutations that may influence the course of cancer. This technology is particularly valuable in the context of personalized medicine, as it helps tailor treatments to the specific genetic makeup of a patient’s tumor, ensuring more effective and targeted therapies. As New Zealand faces a rising incidence of cancer, with over 27,000 new cases reported in 2020 and an expected increase to 52,000 by 2040, the demand for advanced diagnostic tools like NGS is expected to grow. Furthermore, the rising trend and increasing accessibility of NGS technologies, combined with the rapid adoption of digital health solutions, is making it easier for healthcare professionals to integrate genetic insights into routine clinical practice. With the support of governmental initiatives and collaborations with global biotechnological firms, New Zealand is poised to see even greater integration of NGS technologies in its healthcare systems, ultimately enhancing early detection, monitoring, and treatment of various types of cancer.
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT & SERVICES LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE ANALYSIS
4.2 PORTER FIVE FORCES
5 REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 ADVANCEMENTS IN LIQUID BIOPSY TECHNOLOGY
6.1.2 INCREASING INCIDENCE RATE OF CANCER
6.1.3 TECHNOLOGICAL ADVANCEMENT IN GENOMIC SEQUENCING
6.2 RESTRAINTS
6.2.1 HIGH COST OF INSTALLATION AND MAINTENANCE OF EQUIPMENT IN THE LABORATORY
6.2.2 IMPLEMENTATION OF NGS IN THE CLINICAL LAB
6.3 OPPORTUNITIES
6.3.1 INCREASING NUMBER OF PARTNERSHIPS AND COLLABORATION
6.3.2 THE INCREASING PARTICIPATION OF NEW ZEALAND IN GLOBAL ONCOLOGY CLINICAL TRIALS
6.4 CHALLENGES
6.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM NGS
6.4.2 DATA MANAGEMENT ISSUES
7 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY PRODUCTS & SERVICES
7.1 OVERVIEW
7.2 CONSUMABLES
7.2.1 KITS
7.2.2 REAGENTS
7.2.3 OTHERS
7.2.4 LIBRARY PREPARATION AND TARGET ENRICHMENT CONSUMABLES
7.2.5 SAMPLE PREPARATION CONSUMABLES
7.3 INSTRUMENTS
7.3.1 AUTOMATED
7.3.2 SEMI-AUTOMATED
7.3.3 BENCHTOP
7.3.4 STANDALONE
7.4 SERVICES
7.4.1 SEQUENCING SERVICES
7.4.2 DNA SEQUENCING
7.4.3 RNA SEQUENCING
7.4.4 DATA MANAGEMENT SERVICES
8 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY SEQUENCING TYPE
8.1 OVERVIEW
8.2 PAIRED END SEQUENCING
8.3 SINGLE READ SEQUENCING
9 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 TARGETED SEQUENCING
9.3 WHOLE EXOME SEQUENCING
9.4 WHOLE GENOME SEQUENCING
10 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 LUNG CANCER
10.3 BREAST CANCER
10.4 COLORECTAL CANCER
10.5 PROSTATE CANCER
10.6 MELANOMA
10.7 LYMPHOMA
10.8 OTHERS
11 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 PUBLIC
11.2.2 PRIVATE
11.3 CLINICAL LABORATORIES
11.4 ACADEMIC & RESEARCH INSTITUTES
11.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.6 CONTRACT RESEARCH ORGANIZATIONS (CROS)
11.7 OTHERS
12 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.3.1 OFFLINE
12.3.2 ONLINE
12.4 OTHERS
13 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET
14 SWOT ANALYSIS
15 COMPANY PROFILING
15.1 ILLUMINA, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.2 THERMO FISHER SCIENTIFIC INC.
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENTS
15.3 F. HOFFMANN-LA ROCHE LTD
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.4 QIAGEN
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENT
15.5 PACBIO
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENTS
15.6 AGILENT TECHNOLOGIES, INC.
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 BIO-RAD LABORATORIES, INC.
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 CREATIVE BIOLABS
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 DEVYSER
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 MÉRIEUX NUTRISCIENCES CORPORATION
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 MACROGEN OCEANIA
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 MYRIAD GENETICS, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.13 SOPHIA GENETICS
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 TAKARA BIO INC.
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENTS
15.15 ZYMO RESEARCH CORPORATION
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 PRICES OF THE ALL NGS INSTRUMENTS IN 2022
TABLE 2 PRICES OF PLATFORM/COMPANY WISE FOR NGS INSTRUMENTS IN 2022
TABLE 3 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY PRODUCTS & SERVICES, 2018-2032 (USD THOUSAND)
TABLE 4 NEW ZEALAND CONSUMABLES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY PRODUCT TYPE, 2018-2032 (USD THOUSAND)
TABLE 5 NEW ZEALAND CONSUMABLES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 NEW ZEALAND INSTRUMENTS IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY OPERATING MECHANISM, 2018-2032 (USD THOUSAND)
TABLE 7 NEW ZEALAND INSTRUMENTS IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY MODALITY, 2018-2032 (USD THOUSAND)
TABLE 8 NEW ZEALAND SERVICES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 NEW ZEALAND SEQUENCING SERVICES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 10 NEW ZEALAND DATA MANAGEMENT SERVICES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY SEQUENCING TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TECHNOLOGY, 2018-2032 (USD THOUSAND)
TABLE 13 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY CANCER TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 15 NEW ZEALAND HOSPITALS IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 16 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 17 NEW ZEALAND RETAIL SALES IN CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: SEGMENTATION
FIGURE 2 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: DATA TRIANGULATION
FIGURE 3 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: DROC ANALYSIS
FIGURE 4 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: COUNTRY MARKET ANALYSIS
FIGURE 5 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: SEGMENTATION
FIGURE 10 ADVANCEMENTS IN LIQUID BIOPSY TECHNOLOGY ARE DRIVING THE GROWTH OF THE NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET FROM 2025 TO 2032
FIGURE 11 THE TECHNOLOGY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET IN 2025 AND 2032
FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET
FIGURE 13 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY PRODUCTS & SERVICES, 2024
FIGURE 14 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY PRODUCTS & SERVICES, 2025-2032 (USD THOUSAND)
FIGURE 15 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY PRODUCTS & SERVICES, CAGR (2025-2032)
FIGURE 16 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY PRODUCTS & SERVICES, LIFELINE CURVE
FIGURE 17 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY SEQUENCING TYPE, 2024
FIGURE 18 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY SEQUENCING TYPE, 2025-2032 (USD THOUSAND)
FIGURE 19 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY SEQUENCING TYPE, CAGR (2025-2032)
FIGURE 20 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY SEQUENCING TYPE, LIFELINE CURVE
FIGURE 21 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY TECHNOLOGY, 2024
FIGURE 22 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY TECHNOLOGY, 2025-2032 (USD THOUSAND)
FIGURE 23 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY TECHNOLOGY, CAGR (2025-2032)
FIGURE 24 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 25 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY CANCER TYPE, 2024
FIGURE 26 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY CANCER TYPE, 2025-2032 (USD THOUSAND)
FIGURE 27 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY CANCER TYPE, CAGR (2025-2032)
FIGURE 28 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 29 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 30 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 31 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 32 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 33 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 34 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 35 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 36 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 NEW ZEALAND CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING MARKET: COMPANY SHARE 2024 (%)
